Cargando…
Clinical update on linezolid in the treatment of Gram-positive bacterial infections
Gram-positive pathogens are a significant cause of morbidity and mortality in both community and health care settings. Glycopeptides have traditionally been the antibiotics of choice for multiresistant Gram-positive pathogens but there are problems with their use, including the emergence of glycopep...
Autores principales: | Ager, Sally, Gould, Kate |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392139/ https://www.ncbi.nlm.nih.gov/pubmed/22787406 http://dx.doi.org/10.2147/IDR.S25890 |
Ejemplares similares
-
Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia
por: Bi, Li-qing, et al.
Publicado: (2013) -
Linezolid for resistant Gram-positive bacterial infections in children under 12 years: A meta-analysis
por: Wu, Qian, et al.
Publicado: (2022) -
Update on the appropriate use of linezolid in clinical practice
por: Manfredi, Roberto
Publicado: (2006) -
Pharmacokinetic/Pharmacodynamic Analysis of Tedizolid Phosphate Compared to Linezolid for the Treatment of Infections Caused by Gram-Positive Bacteria
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2021) -
143. Modification of Linezolid Restriction Criteria Reduces ICU Gram-positive Antibiotic Consumption
por: Boulos, John M, et al.
Publicado: (2020)